Journal of Cholesterol and Heart Disease

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Cholesterol and Heart Disease (2022) Volume 6, Issue 4

Effect of Statins in Patients with COVID-19.

Jingpu Zhang*

Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA

*Corresponding Author:
Jingpu Zhang
Department of Neurosurgery
Jacobs School of Medicine and Biomedical Sciences
University at Buffalo, Buffalo, New York, USA

Received: 29-Jul-2022, Manuscript No. AACHD-22-73644; Editor assigned: 01-Aug-2022, PreQC No. AACHD-22-73644(PQ); Reviewed: 16-Aug-2022, QC No. AACHD-22-73644; Revised: 19-Aug-2022, Manuscript No. AACHD-22-73644(R); Published: 26-Aug-2022, DOI: 10.35841/aachd-6.4.117

Citation: Zhang J. Effect of Statins in Patients with COVID-19. J Cholest Heart Dis. 2022; 6(4):117

Visit for more related articles at Journal of Cholesterol and Heart Disease


Statins hinder the basic step of cholesterol blend in which 3-hydroxy-3-methylglutaryl coenzyme A (HMGC) is changed to mevalonate by the chemical HMGC reductase. By doing so, they have a powerful lipid-lowering impact that decreases cardiovascular chance and diminishes mortality. Since the mevalonate pathway moreover impacts endothelial work, the incendiary reaction, and coagulation, the impacts of statins reach well past their cholesterol bringing down properties. As with all drugs, statins may have antagonistic impacts; these incorporate musculoskeletal indications, expanded hazard of diabetes, and higher rates of hemorrhagic stroke. In any case, the recurrence of unfavorable impacts is greatly moo and, in chosen persistent populaces, the benefits of statins significantly exceed the potential dangers.


Statins, Myositis, Diabetes, Stroke, Adverse effects


Since the event of novel coronavirus illness 2019 (COVID-19) widespread, there have been numerous talks on the repurposing of existing drugs for the treatment of COVID-19, one of which is the statins. In any case, there are two restricting sees on the impacts of statins on the clinical course of COVID-19. Dysregulation of the myeloid separation essential reaction protein (MYD) 88 pathway which comes about in overpowering aggravation has been watched and related with destitute forecast in other coronavirus contaminations; this may be the case for COVID-19 but has not been conclusively demonstrated Statins are known inhibitors of MYD and may stabilize MYD levels within the nearness of outside stressors, which in this way recommend their parts in ensuring COVID-19 patients from the advancement of overwhelming inflammatory responses. Besides, statins are known to tentatively up-regulate ACE2 expression, and so may be defensive towards lung damage actuated by coronavirus [1].

On the other hand, statins cause lack of endogenous cholesterol substance within the cells, driving to up regulation of lowdensity lipoprotein receptors, which in turn comes about in steady consolidation of exogenous cholesterol onto the cell film and the ensuing arrangement of numerous lipid flatboats, hence upgrading availability for coronaviruses. A few researchers have too contended that statins might advance the advancement of a more serious course of COVID-19 due to enactment of the inflammation pathway in intense respiratory trouble disorder, driving to expanded pro-inflammatory interleukin-18 levels and ensuing cytokine store. Person observational ponders have since detailed on this region and we carried out a meta-analysis to summarize the existing prove on the impact of statins on the clinical results of COVID-19 from balanced examinations [2].

In spite of the fact that statins have been detailed to extend serum levels of liver proteins, statin organization is as it were once in a while related with genuine liver harm. It has been evaluated in post-marketing ponders that the chance of liver damage may be around 1 case per users. Be that as it may, its causal affiliation with statins has not been proved however. It is additionally imperative to consider that the “liver enzymes” aspartate aminotransferase and alanine aminotransferase are too display in skeletal muscle. In this way, muscle poisonous quality seem lead to expanded levels of “liver enzymes”. Assurance of creatine kinase and gamma-glutamyl transferase may be supportive to recognize muscle from liver inclusion in these patients, as creatine kinase elevation demonstrates muscle harm, whereas an increment within the gammaglutamyl transferase is related with liver harm [3].

Observational thinks about recommended that patients treated with statins may have an expanded hazard of hemorrhagic stroke. Blood cholesterol levels are contrarily related with the rates of hemorrhagic stroke, particularly in patients with concomitant tall blood pressure. In randomized trials and meta-analyses, indeed in spite of the fact that the hazard of ischemic stroke was diminished, the hazard of creating a hemorrhagic stroke was expanded by utilizing statins. It has been assessed that there's an expanded risk within the rate of this complication, which implies an abundance of cases per 10,000 patients treated for years. This chance is more noteworthy in patients with past cerebrovascular infection and populaces with a tall chance of hemorrhagic stroke like Asian individuals [4,5].


In conclusion, statins are profoundly compelling drugs that have the capacity to diminish the chance of major cardiovascular occasions up to in essential avoidance and 5% in auxiliary anticipation over 5 a long time. In any case, approximately patients over this same period of time may create side impacts, most of them mellow. In any case, given the incredible number of patients beneath statin treatment, these unfavorable impacts will be common in clinical hone and hence, must be well-known by the restorative community in arrange to be instantly analyzed and accurately overseen.


  1. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad. 2010; 86(5):484-93.
  2. Indexed at, Google Scholar, Cross Ref

  3. Alberts AW, Chen J, Kuron G, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci. 1980; 77(7):3957-61.
  4. Indexed at, Google Scholar, Cross Ref

  5. Lennarz WJ. Lipid Linked Sugars in Glycoprotein Synthesis: The oligosaccharide chain of certain glycoproteins is preassembled on a polyprenol carrier. Science. 1975;188(4192):986-91.
  6. Indexed at, Google Scholar, Cross Ref

  7. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007; 49(23):2231-7.
  8. Indexed at, Google Scholar, Cross Ref

  9. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006; 6(5):358-70.
  10. Indexed at, Google Scholar, Cross Ref

Get the App